Alumis Inc SEC Filings

Alumis Inc. (ALMS) insider James B. Tananbaum, a director and 10% owner, reported buying additional common stock through affiliated investment entities. On 11/21/2025, an indirect account purchased 72,212 Alumis common shares at a price of $7.38 per share, reported as an acquisition. After this transaction, multiple affiliated Foresite Capital and Foresite Labs funds and vehicles are shown as beneficially owning various blocks of Alumis stock, all reported as indirect ownership.

The filing explains that several limited partnerships and LLCs, including Foresite Capital Opportunity Fund V, Foresite Capital Fund V and VI, and multiple Foresite Labs vehicles, hold the shares of record. Management entities and Mr. Tananbaum may be deemed to have voting and dispositive power over these holdings, but he formally disclaims group status and beneficial ownership beyond his pecuniary interest in each entity.

Alumis Inc. (ALMS)11/21/2025, a reporting person bought 72,212 shares of common stock at $7.38 per share, recorded as an indirect holding.

After this transaction, the reporting person reports indirect beneficial ownership of multiple large Alumis positions through affiliated Foresite investment vehicles. These include 2,614,215 shares held by Foresite Capital Opportunity Fund V, L.P., 4,247,670 shares held by Foresite Capital Fund VI, L.P., 5,584,889 shares held by Foresite Capital Fund V, L.P., and additional blocks of 194,459, 1,960,337, and 1,176,470 shares held by other Foresite-related entities.

The filing notes that the various Foresite funds and management entities, including James B. Tananbaum, may be deemed to share voting and dispositive power over these shares but each disclaims being part of a "group" and disclaims beneficial ownership beyond their pecuniary interests.

Alumis Inc. (ALMS) reported an insider share purchase on a Form 4 by a director associated with Samsara investment entities. On 11/20/2025, the reporting person, through Samsara Opportunity Fund, L.P., purchased 125,743 shares of common stock in an open-market transaction at a weighted average price of $7.20 per share, with individual trades occurring between $6.92 and $7.48. Following this transaction, Samsara Opportunity Fund, L.P. was shown as holding 643,260 shares indirectly attributed to the reporting person, and Samsara BioCapital, L.P. was shown as holding an additional 4,491,731 shares indirectly. The reporting person indicates that beneficial ownership of these positions is disclaimed except to the extent of any pecuniary interest.

Alumis Inc. (ALMS) reported insider share purchases by a director affiliated with Foresite entities. On 11/17/2025, the reporting person acquired 50,000 shares of common stock at $5.60 and 150,000 shares at $5.59. On 11/18/2025, a further 117,374 shares were purchased at $6.19, followed by 190,500 shares at $6.56 on 11/19/2025, all reported as indirect ownership.

After these transactions, the Form 4 shows 2,542,003 Alumis shares beneficially owned indirectly under footnote (1), with additional indirect beneficial holdings of 4,247,670, 5,584,889, 194,459, 1,960,337 and 1,176,470 shares through various Foresite Capital and Foresite Labs funds and entities, each with specified control structures and standard beneficial ownership disclaimers.

Alumis Inc. (ALMS) received a series of insider share purchases by Foresite-affiliated funds and entities whose managing member, James B. Tananbaum, serves as a director of the company. Between 11/17/2025 and 11/19/2025, these reporting persons purchased a combined 507,874 shares of Alumis common stock in open-market transactions at prices ranging from $5.60 to $6.56 per share.

After these transactions, the reporting persons report indirect beneficial ownership of several large blocks of Alumis stock, including 4,247,670 shares held by Foresite Capital Opportunity Fund V, L.P. and 5,584,889 shares held by Foresite Capital Fund VI, L.P., along with additional stakes held by related funds and co-investment vehicles as detailed in the footnotes.

Alumis Inc. (ALMS) director and 10% owner James B. Tananbaum reported multiple open-market purchases of the company’s common stock. On November 17–19, 2025, entities he is associated with bought a total of 507,874 shares at prices ranging from $5.59 to $6.56 per share, increasing his indirect beneficial ownership in Alumis. The shares are held across several Foresite-affiliated investment vehicles, including Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Foresite Capital Fund V, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. Tananbaum reports potential voting and dispositive power through these entities but disclaims group status and beneficial ownership beyond his pecuniary interest.

Alumis Inc. (ALMS) director Srinivas Akkaraju reported open-market purchases of Alumis common stock made through affiliated investment funds.

On 11/17/2025, Samsara Opportunity Fund, L.P. bought 914 shares at a weighted average price of $5.51. On 11/18/2025, it purchased 102,652 shares at a weighted average of $6.05, and on 11/19/2025 it bought 137,772 shares at a weighted average of $6.56. After these transactions, the reporting person is deemed to beneficially own 517,517 shares held by Samsara Opportunity Fund, L.P. and 4,491,731 shares held by Samsara BioCapital, L.P., with beneficial ownership disclaimed except for any pecuniary interest.

Alumis Inc. (ALMS) director Srinivas Akkaraju reported an indirect purchase of common stock. On 11/13/2025, 276,179 shares of Alumis common stock were acquired at a price of $5.25 per share in a privately negotiated transaction. The shares were purchased by Samsara Opportunity Fund, L.P. from Samsara BioCapital, L.P., both investment entities with which the reporting person is affiliated.

Following this transaction, 276,179 shares are held through Samsara Opportunity Fund, L.P., and 4,491,731 shares are held through Samsara BioCapital, L.P. The filing notes that the transfer between these entities did not change the reporting person’s overall beneficial ownership, and that he disclaims beneficial ownership in these securities except to the extent of his pecuniary interest.

Alumis Inc. reported Q3 2025 results showing a net loss of $110.8 million as R&D spending of $97.8 million and G&A of $19.5 million outweighed $2.1 million of collaboration revenue. For the nine months, total revenue was $22.1 million (license $17.4 million; collaboration $4.7 million), and net loss was $150.4 million, reflecting a $187.9 million gain on bargain purchase from the ACELYRIN merger.

The company completed the ACELYRIN Merger on May 21, 2025, issuing 48,653,549 shares as consideration of $238.1 million for net assets with a fair value of $426.0 million, and recognized a $10.7 million deferred tax liability tied to acquired IPR&D.

As of September 30, 2025, cash and cash equivalents were $65.3 million and marketable securities were $312.5 million; stockholders’ equity was $384.8 million. Operating cash outflow for the nine months was $297.6 million. Management states the $377.7 million in cash, cash equivalents and marketable securities provides at least 12 months of funding. As of November 6, 2025, voting shares outstanding were 97,208,495 and non‑voting shares were 7,184,908.